AU Patent

AU2010203512C1 — Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Assigned to Curis Inc · Expires 2013-10-17 · 13y expired

What this patent protects

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3 -kinase related diseases and disorders such as cancer. The instant application further relates to…

USPTO Abstract

The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3 -kinase related diseases and disorders such as cancer. The instant application further relates to the the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Drugs covered by this patent

Patent Metadata

Patent number
AU2010203512C1
Jurisdiction
AU
Classification
—
Expires
2013-10-17
Drug substance claim
No
Drug product claim
No
Assignee
Curis Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.